论文部分内容阅读
心血管病药物治疗经历了200余年的发展史。1785年英国医师WhitheringW报告紫花洋地黄治疗水肿有效,成为心血管病药物治疗的第一个范例。20世纪60年代开始,随着病理生理学和药理学的进步,β受体阻滞剂、钙拮抗剂、血管紧张素转化酶抑制剂、血管紧张素受体拮抗剂及他汀类药物的相继发现和临床应用,为心血管病治疗学建立了一个个重要的里程碑。随着现代分子生物学、细胞生物学、免疫学等相关学科的迅猛发展,心血管病治疗学研究已转向针对病理生理环节中的关键分子,使心血管病治疗学进入分子靶向治疗时代。心血管病靶向治疗作为一种新的治疗学理念于2005年6月17～19日在中国武汉《国际心血管病靶向治疗论坛》上提出,本刊邀请国内外著名专家撰写心血管病相关靶向治疗研究进展,探讨心血管病治疗的新途径,以飨读者。
Cardiovascular drug treatment has experienced more than 200 years of development history. In 1785 British physician WhitheringW reported that digitalis was effective in treating edema and became the first example of drug therapy for cardiovascular disease. Since the 1960s, with the progress of pathophysiology and pharmacology, the successive discovery of beta blockers, calcium antagonists, angiotensin converting enzyme inhibitors, angiotensin receptor blockers and statins and Clinical application has set an important milestone for the treatment of cardiovascular diseases. With the rapid development of modern molecular biology, cell biology, immunology and other related disciplines, the study of cardiovascular disease treatment has turned to the key molecules in the pathophysiology, making the treatment of cardiovascular diseases into the era of molecular targeted therapy. Cardiovascular disease targeted therapy as a new concept of treatment in June 17, 2005 19 ~ 19 in Wuhan, China “International Cardiovascular Disease Targeted Therapy Forum” put forward, the magazine invited renowned experts at home and abroad to write cardiovascular disease Related research advances in targeted therapies to explore new ways of treating cardiovascular diseases in order to readers.